Silvia M Bacot
Overview
Explore the profile of Silvia M Bacot including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
168
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Taylor C, Patterson K, Friedman D, Bacot S, Feldman G, Wang T
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272928
Antibody-drug conjugates (ADCs) consist of an antibody backbone that recognizes and binds to a target antigen expressed on tumor cells and a small molecule chemotherapy payload that is conjugated to...
2.
Wang T, Denman D, Bacot S, Feldman G
Biomedicines
. 2022 May;
10(5).
PMID: 35625917
While promising, PD-L1 expression on tumor tissues as assessed by immunohistochemistry has been shown to be an imperfect biomarker that only applies to a limited number of cancers, whereas many...
3.
Harper T, Bacot S, Fennell C, Matthews R, Zhu C, Yue P, et al.
Int J Mol Sci
. 2021 Nov;
22(21).
PMID: 34769278
Immune checkpoint inhibitor (ICI) therapy has revolutionized anti-cancer treatment for many late-stage cancer patients. However, ICI therapy has thus far demonstrated limited efficacy for most patients, and it remains unclear...
4.
Bacot S, Harper T, Matthews R, Fennell C, Akue A, KuKuruga M, et al.
Int J Mol Sci
. 2020 Dec;
21(23).
PMID: 33261003
The absence of reliable, robust, and non-invasive biomarkers for anti- Programmed cell death protein 1 (PD-1) immunotherapy is an urgent unmet medical need for the treatment of cancer patients. No...
5.
Luo S, McSweeney K, Wang T, Bacot S, Feldman G, Zhang B
MAbs
. 2019 Nov;
12(1):1685814.
PMID: 31774346
Therapeutic monoclonal antibodies (mAbs) are commonly administered to patients through intravenous (IV) infusion, which involves diluting the medication into an infusion solution (e.g., saline and 5% dextrose). Using the wrong...
6.
Yue P, Harper T, Bacot S, Chowdhury M, Lee S, Akue A, et al.
Oncoimmunology
. 2018 Dec;
8(1):e1512456.
PMID: 30546949
Immune checkpoint inhibitors (ICIs) such as the anti-PD-1 antibody Nivolumab, achieve remarkable clinical efficacy in patients with late stage cancers. However, only a small subset of patients benefit from this...
7.
Bacot S, Feldman G, Yamada K, Dhawan S
Virology
. 2015 Jan;
476:372-376.
PMID: 25589240
Transfusion of blood and blood products contaminated with the pathogenic form of prion protein Prp(sc), thought to be the causative agent of variant a Creutzfeldt-Jakob disease (vCJD), may result in...
8.
Swisher J, Burton N, Bacot S, Vogel S, Feldman G
Blood
. 2009 Dec;
115(3):549-58.
PMID: 19965653
Annexins are a large family of intracellular phospholipid-binding proteins, yet several extracellular roles have been identified. Specifically, annexin A2, found in a heterotetrameric complex with S100A10, not only serves as...
9.
Bacot S, Lenz P, Frazier-Jessen M, Feldman G
J Leukoc Biol
. 2003 Jul;
74(1):118-25.
PMID: 12832450
Specific prion peptides have been shown to mimic the pathologic isoform of the prion protein (PrP) and to induce a neurotoxic effect in vitro and in vivo. As monocytic cells...
10.
Lenz P, Thompson C, Day P, Bacot S, Lowy D, Schiller J
Clin Immunol
. 2003 Apr;
106(3):231-7.
PMID: 12706410
Papillomavirus-like particles (VLPs) are potent inducers of humoral and cellular immune responses, making them attractive candidates for noninfectious viral subunit vaccines. To further our understanding of how VLPs activate the...